



**Telix Pharmaceuticals Limited**  
ACN 616 620 369  
Suite 401, 55 Flemington Road  
North Melbourne  
Victoria, 3051  
Australia

---

## **Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations**

Melbourne (Australia) – 12 July 2021. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') is pleased to announce that Ms. Kyahn Williamson has joined the Telix executive leadership team in the role of Senior Vice President of Corporate Communications and Investor Relations.

Kyahn joins Telix from WE Communications, where she was Group Head of Investor and Corporate Communication. Over the past 15 years, Kyahn has worked with a wide range of ASX-listed companies spanning the medtech and biotech sectors, designing and implementing investor relations and public relations strategies, and advising across multiple IPOs and M&A transactions.

Ms. Williamson stated, "I'm absolutely delighted to join the team and apply my deep industry experience to support Telix as it makes the transition to a commercial stage company focused on delivering unmet patient need. With this transition comes a very distinct set of communications and investor relations needs. I look forward to joining the senior executive to continue to build Telix's reputation as a global leader in diagnostic and therapeutic applications of molecularly-targeted radiation."

Telix CEO, Dr. Christian Behrenbruch added, "On behalf of the global team, I am delighted to welcome Kyahn to the business at such a critical juncture. Ky led our IPO communications back in 2017 and with the Company reaching key commercial milestones, it's a real privilege for us to have such a capable communications professional leading our corporate comms and investor relations activity."

### **About Telix Pharmaceuticals Limited**

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit [www.telixpharma.com](http://www.telixpharma.com) and follow Telix on [Twitter](https://twitter.com/TelixPharma) (@TelixPharma) and [LinkedIn](https://www.linkedin.com/company/telix-pharmaceuticals).

Telix's lead investigational product, Illuccix<sup>®</sup> (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,<sup>1</sup> and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).<sup>2</sup> Telix is also progressing marketing authorisation applications for Illuccix<sup>®</sup> in the European Union<sup>3</sup> and Canada.<sup>4</sup> None of Telix's products have received a marketing authorisation in any jurisdiction.

### **Telix Corporate Contact**

Dr. Christian Behrenbruch  
Telix Pharmaceuticals Limited  
Managing Director and CEO  
Email: [chris.behrenbruch@telixpharma.com](mailto:chris.behrenbruch@telixpharma.com)

### **Telix Investor Relations**

Kyahn Williamson  
Telix Pharmaceuticals Limited  
SVP Corporate Comms and Investor Relations  
Email: [kyahn.williamson@telixpharma.com](mailto:kyahn.williamson@telixpharma.com)

---

<sup>1</sup> ASX disclosure 24/11/20.

<sup>2</sup> ASX disclosure 14/04/21.

<sup>3</sup> ASX disclosure 1/05/20.

<sup>4</sup> ASX disclosure 16/12/20.

---

#### Important Information

*This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.*